Today in B2B: Cyber Monday Numbers and An Olympic Goal

 

We are quickly approaching the 2020 Tokyo Olympics, but preparations are already underway for the 2028 Games in Los Angeles.

The city has partnered with the private sector on a plan to have 30 percent of cars on LA’s roadways be electric by the times the games begin.

According to smartcitiesdive.com, LA’s plan will have an increase in ride-sharing options, and a goal to convert 20 percent of all trips in single-occupancy vehicles to zero-emission public transit options like bicycles.

Meanwhile in the here and now, the numbers are already in for Cyber Monday’s shopping bonanza.

According to Adobe research, more than $9.2 billion was spent on Cyber Monday, good for a year-over-year increase of 17 percent.

Something else notable Adobe reported was that online sales conducted through smartphone hit a record $3 billion. That is an increase of 46 percent over last year, signaling a shift in the way brands reach their customers.

Taking a look at the trade show calendar, a huge event in the medical world is taking place this week. That would be Pri-Med East in Boston, Mass.

Keynote speakers include Massachusetts Governor Charlie Baker and former NBA player and motivational speaker Chris Herren. Topics on the agenda include everything from telehealth to primary care best practices. The event runs through Saturday afternoon.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More